What are the Challenges in Targeting BER in Cancer?
Targeting BER in cancer therapy presents several challenges. One major issue is selectivity; inhibitors must selectively target cancer cells without affecting normal cells to minimize side effects. Additionally, the redundancy and complexity of the DNA repair pathways mean that inhibiting one pathway can activate compensatory mechanisms, reducing the efficacy of the treatment. Further research is needed to develop targeted therapies that can effectively exploit BER deficiencies in cancer cells.
